Cyrille Touzeau

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate...

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

Abstract In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in tran...